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ABSTRACT 
 
The last several years have seen unprecedented advances in deciphering the genetic etiology 
of autism spectrum disorders (ASDs). Heritability studies have repeatedly affirmed a 
contribution of genetic factors to the overall disease risk. Technical breakthroughs have enabled 
the search for these genetic factors via genome-wide surveys of a spectrum of potential 
sequence variations, from common single-nucleotide polymorphisms to essentially private 
chromosomal abnormalities. Studies of copy-number variation have identified significant roles 
for both recurrent and nonrecurrent large dosage imbalances, although they have rarely 
revealed the individual genes responsible. More recently, discoveries of rare point mutations 
and characterization of balanced chromosomal abnormalities have pinpointed individual ASD 
genes of relatively strong effect, including both loci with strong a priori biological relevance and 
those that would have otherwise been unsuspected as high-priority biological targets. Evidence 
has also emerged for association with many common variants, each adding a small individual 
contribution to ASD risk. These findings collectively provide compelling empirical data that the 
genetic basis of ASD is highly heterogeneous, with hundreds of genes capable of conferring 
varying degrees of risk, depending on their nature and the predisposing genetic alteration. 
Moreover, many genes that have been implicated in ASD also appear to be risk factors for 
related neurodevelopmental disorders, as well as for a spectrum of psychiatric phenotypes. 
While some ASD genes have evident functional significance, like synaptic proteins such as the 
SHANKs, neuroligins, and neurexins, as well as fragile x mental retardation–associated 
proteins, ASD genes have also been discovered that do not present a clear mechanism of 
specific neurodevelopmental dysfunction, such as regulators of chromatin modification and 
global gene expression. In their sum, the progress from genetic studies to date has been 
remarkable and increasingly rapid, but the interactive impact of strong-effect genetic lesions 
coupled with weak effect common polymorphisms has not yet led to a unified understanding of 
ASD pathogenesis or explained its highly variable clinical expression. With an increasingly firm 
genetic foundation, the coming years will hopefully see equally rapid advances in elucidating the 
functional consequences of ASD genes and their interactions with environmental/experiential 
factors, supporting the development of rational interventions. 
 
TEXT 
 
Pervasive developmental disorders are a cluster of common, complex conditions characterized 
by impairments in social interactions and communication, as well as repetitive or stereotypic 
behaviors. This cluster of neurodevelopmental abnormalities is more commonly referred to as 
autism spectrum disorders (ASDs), which by DSM-IV criteria include narrowly defined autism, 
social disintegration disorder, Asperger’s disorder, and pervasive developmental disorder not 
otherwise specified. Few empirical data suggest distinct etiologies among subgroups, however, 
and the ongoing revisions to the Diagnostic and Statistical Manual of Mental Disorders reduce 
these phenotypic subgroups to a single ASD diagnostic classification. 
 The prevalence of ASD has been steadily rising, accompanied by widespread 
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speculation concerning the factors that may be responsible.1–6 In the 1970s and 1980s, 
prevalence was estimated at ~0.5 per 1000.7,8 The most recent population-based study from 
2008 suggests at least a tenfold increase, with the prevalence of ASD among eight-year-old 
children across 11 sites now estimated at 11.3 per 1,000 (1 in 88) but varying widely among 
sites (range = 4.8–21.2 per 1000).9 A portion of the increase in prevalence over the past 
decades is likely attributable to changes in diagnostic classifications.6 Even among similar study 
designs and populations, however, a detectable and consistent rise in estimated prevalence is 
evident over a relatively short period of time, from 6.7 per 1000 based on 2000 data10 to 9.0 per 
1000 based on 2006 data11 and 11.0 per 1000 based on 2008 data.9 This increase has been 
speculated to arise in part from increasing awareness of the disorder,9 and quantifying the 
changes in prevalence over time in the absence of an accepted, quantitative diagnostic 
biomarker is a significant challenge. Nevertheless, these data leave little doubt that ASD is a 
common, devastating developmental disorder with a severe public health impact both in the 
United States and globally. 	
• array comparative genomic hybridization: a technology used to identify copy number 
variations in a DNA sample 
• Autism Genetic Resource Exchange: a biobank and data repository for autism research 
• balanced chromosomal rearrangement (BCR): the exchange of DNA between two or 
more chromosomes without cytogenetically detectable gain or loss of DNA 
• copy-number variation (CNV): genetic variation involving the gain or loss of segments of 
DNA. 
• genome-wide association study (GWAS): the use of genome-wide SNP chip genotyping 
technologies to discover genetic variations associated with a phenotype 
• loss of function (LoF): the loss of a gene’s ability to perform its native function, due to 
deletion or mutation 
• non-allelic homologous recombination (NAHR): a process by which genomic segments 
located between segments of homologous sequence can be gained or lost due to the 
improper pairing, breakage and rejoining of those homologous flanking regions 
• next-generation sequencing: highly parallel short-read DNA sequencing technology 
• runs of homozygosity: regions of an individual’s genome where all maternal and paternal 
alleles are identical, often due to consanguinity 
• single-nucleotide polymorphism (SNP): a change in a single DNA base pair, found in the 
population 
• single-nucleotide variant:  a change in a single DNA base pair change, including private 
and de novo mutations not normally seen in the population 
• structural variation (SV): any rearrangement in the structure of genomic DNA, including 
CNVs and BCRs 
• whole-exome sequencing (WES): the use of next-generation sequencing on only the 
exonic, or protein-coding, portion of a genome 
• whole-genome sequencing: the use of next-generation sequencing on a whole genome 
Text Box 1. Technical terms 
 Given the increasing prevalence, the relative importance of genetic versus 
environmental factors in the etiology of ASD is a matter of ongoing debate. It is likely that these 
factors act in interaction, given the overwhelming evidence indicating indicate a substantial 
genetic component. The high heritability of autism has been well established since the late 
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1980s. A meta-analysis of twin studies and case reports found an average monozygous twin 
concordance of 64% and an average dizygous twin concordance of 9%, compared to a 
population prevalence estimated to be 0.05% at the time of the study.12 A large family-based 
study estimated recurrence risk—the probability that any given child born after the first autistic 
child in a family will show signs of autism—at 8.6%8, although more recent studies have found 
higher concordance among dizygous twins.13,14 Heritability estimates for ASD have thus ranged 
from as high as 90% under a multifactorial threshold model15 to a recent study with a much 
lower estimate of ~37%, albeit with a wide confidence interval.14 A more detailed discussion of 
heritability estimates is outside the scope of this review. Despite the wide range in point 
estimates of heritability, it is clear that ASD has a large heritable component. It is also clear, 
however, that expressivity of the disorder is significantly influenced by nongenetic factors. Given 
that the human genome, unlike the environment that we experience, represents a defined, finite 
space in which to search for risk factors, there has been ample motivation for investigating the 
genetic underpinnings of ASD. This search has been facilitated by the dramatic increase in the 
power of modern genetic technologies, and in the following review, we offer one vantage on 
what has been a remarkable half-decade of progress in ASD genetics. We also temper this 
enthusiasm with the knowledge that the pathogenic mechanisms by which the contributing 
genes operate remain unknown in most individuals, and that novel, broadly applicable 
therapeutic interventions have not yet been developed based upon this progress.  
We focus here on five seminal findings in the last several years in defining the genetic 
architecture of ASD. First, it has become clear that the genetic contribution to ASD comprises a 
diversity of mutational mechanisms, including rare single-nucleotide variants,16–23 copy-number 
variations (CNVs),24–31 chromosomal abnormalities,26,32 and common polymorphic variation (see 
Figure 1).33–36 Second, highly penetrant de novo variations that disrupt normal gene dosage can 
have a major impact on ASD risk.19,22,23,26–31,37 Third, regions of recurrent rearrangements occur 
in a measurable proportion of ASD subjects,38 and their phenotypic impact can, at times, be 
attributed to a single strong-effect locus within the region.26,39–41 Fourth, genes that contribute to 
ASD represent diverse biological pathways and include not only participants in synaptic 
function21,42 but also genes involved in global regulation of transcript expression and epigenetic 
modification.18,19,26,43 Finally, many genes associated with ASD confer shared risk to a wide 
range of neurodevelopmental abnormalities and psychopathology.26,44 Collectively, these data 
have provided an emerging portrait of a genetic architecture of ASD in which a highly 
heterogeneous collection of genes can contribute to a similar clinical presentation; at the same 
time, specific genetic lesions can be associated with widely variable clinical outcomes. In this 
review, we describe recent breakthroughs in the genetic etiology of ASD and their implications 
for our understanding of the models of ASD pathogenesis. 
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Figure 1. Genes and loci reported to significantly affect autism risk. Protein-coding single 
nucleotide variants and small insertions/deletions discovered through exome sequencing, 
unbalanced structural variation (whole-gene or chromosomal region deletions and duplications), 
and balanced structural variation (translocations, inversions, and chromothripsis) affect risk 
through overlapping sets of genes and loci. Signals reported in genome-wide association 
studies are also shown. 
GENE DISCOVERY 
 
The number of definitive genetic risk factors for ASD that have been discovered in recent years 
compared to the preceding decade of research has been remarkable. Thanks to revolutionary 
technical leaps such as oligonucleotide microarrays and massively parallel sequencing, coupled 
with clever methodological innovations, genetic studies have elucidated a large number of 
unambiguous risk loci in ASD, ranging from large genomic regions to individual nucleotides. 
Moreover, there are many additional loci that, given the modest sample sizes studied to date in 
ASD, have not met the stringent criteria of reproducible statistical significance but that represent 
promising new leads warranting further investigation. 
 Prior to emergence of the capacity to perform unbiased genome-wide surveys of 
individual nucleotides and genome structure, precious little was known about the genetic 
architecture of ASD other than its comorbidity with several other Mendelian disorders, including 
Fragile X syndrome, Rett’s syndrome, tuberous sclerosis, neurofibromatosis, Angelman 
syndrome, and macrocephaly associated with PTEN mutations.45–52 In addition, candidate gene 
studies, while largely unreliable due to many false-positive findings, did identify associations of a 
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handful of genes that continue to be associated with ASD in some studies: those expressed as 
neuroligins,53 SHANK,54 and CNTNAP.55 
 The development of array-based technologies to detect relative DNA dosage changes, 
as well as technology capable of simultaneously genotyping hundreds of thousands to millions 
of single-nucleotide polymorphisms (SNPs), first opened the door to unbiased genome-wide 
assessment of loci conferring risk to ASD in an association-based design. The next technical 
advance came with the advent of massively parallel sequencing and, with it, methods to reduce 
the complexity of the genome by enriching for targeted regions, such as whole-exome capture, 
which surveys the approximately 1% of the genome comprising known protein-coding 
sequences. We highlight the most significant findings of the last several years from each major 
approach taken in ASD genetics. This is not meant to be a comprehensive review of the existing 
studies or of each gene implicated, but rather a review of the seminal findings from each 
approach, with a synthesis of the most significant loci elucidated from those studies. 
 
SINGLE-NUCLEOTIDE VARIANTS 
Genome Wide Association Studies 
 
Both common-variant and rare-variant hypotheses have been suggested to explain the genetics 
of ASD, but the advent of genome-wide, SNP-based microarrays enabled a much earlier test of 
the former in an unbiased genome-wide association study (GWAS), with carefully determined 
thresholds for statistical significance. The method has been extremely productive in identifying 
disease-associated SNPs across a broad array of human diseases. As of 23 January 2014, 
1,789 GWAS studies have been published, identifying 7,196 trait-associated SNPs at genome-
wide  statistical significance (www.genome.gov/gwastudies).56 The ultimate success of GWAS 
in psychiatric genetics was initially uncertain, but a seminal publication by Purcell and 
colleagues57 established a reproducibly significant effect of polygenic variation in schizophrenia 
and bipolar disorder. Published meta-analyses have begun to uncover genome-wide significant 
loci in schizophrenia,58 and as power is increased from the accumulation of sufficiently large 
sample sizes, ongoing large-scale studies across psychiatric disorders suggest the comparable 
impact of common variation in neuropsychiatric disorders on many other traits.44 These studies 
also suggest a significant degree of shared genetic risk among multiple neurodevelopmental 
and psychiatric disorders. Discoveries of subtle effects from common variation in ASD alone 
have been far more incremental; it is unknown whether these results reflect the genetic 
architecture of the disorder or a limitation due to sample size and the power of studies to date. 
GWAS and family-linkage analyses from SNP microarrays in three studies performed thus far33–
35 identified independent genome-wide significant associations, but a meta-analysis of these 
studies did not support consistent effects of any of the loci.59 More recently, Devlin and 
colleagues36 have showed that common variants exerting weak additive effects collectively 
represent a major component of ASD risk. It remains noteworthy that none of the existing ASD 
GWAS studies approached the power that has been achieved from the amalgamation of 
samples in other disorders, and that the overall contribution of common variation in ASD likely 
remains an underestimate of its true effect. 
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Exome Sequencing 
 
Since 2010, the continued decline in the price of next-generation sequencing, combined with the 
banking of genetic material and phenotypic data from ASD probands and their families by the 
Simons Simplex Collection,60 the Autism Genetic Resource Exchange,61 and the Autism 
Consortium of Boston (www.autismconsortium.org), has allowed the emergence of whole-
exome sequencing (WES) as a powerful new tool for exploring the genetic etiology of ASD. 
Studies of the contribution of rare and de novo coding variation in exomes have uncovered 
several previously unreported gene associations, confirmed advanced parental age as a 
significant risk factor for increased de novo mutation rates, and implicated particular biological 
pathways. Different hypotheses as to the nature of causal coding variations have motivated 
exome sequencing under a variety of study designs. 
 
Rare complete knockouts in outbred populations 
 
Healthy individuals are estimated to carry ~100 total loss-of-function (LoF) mutations per 
genome.62 A recessive model of ASD inheritance would suggest that some ASD individuals 
have chance combinations of deleterious LoF alleles for critical genes, resulting in a “complete 
knockout” homozygous, compound heterozygous, or hemizygous state. WES has been 
employed in a case-control study design to demonstrate that across all genes in the genome, 
the occurrence of such rare complete knockouts is indeed enriched approximately twofold 
relative to controls in subjects with ASD, with a trend toward greater enrichment for brain-
expressed genes.17 For genes on the X chromosome, male cases also showed enrichment 
relative to male controls for hemizygous inactivating mutations. Complete knockouts were 
nonetheless rare in cases and in controls, and a recessive LoF mode of inheritance was 
estimated to explain just ~5% of ASD cases (3% by autosomes, and 2% by the X chromosome). 
The excess of affected males in ASD motivated an effort to sequence only the X chromosome 
exome in concordant ASD male sibling pairs, which identified several possibly causal LoF 
mutations, including three in genes otherwise associated with intellectual disability or with 
autism via CNVs63—that is, genetic variations involving the gain or loss of DNA segments. 
 
Complete knockouts in chromosomes identical by descent 
 
The combination of recessive LoF alleles into a homozygous complete-knockout state is more 
likely to occur in genomes rich in runs of homozygosity, as these genomes may represent the 
convergence in an individual of two copies of the same ancestral chromosome being inherited 
from both parental lineages. Studies illuminating the contribution of such recessive alleles to 
ASD have taken advantage of the elevated homozygosity found in consanguineous families, 
isolated populations, and a small fraction of individuals whose parents are not known to be 
related. One study, which specifically targeted multiplex consanguineous families with multiple 
ASD individuals in order to enrich for such homozygous-inactivating mutations, performed WES 
and then filtered for rare alleles that were homozygous in all affected individuals and 
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heterozygous or absent in all unaffected individuals.16 Functional experiments in that study 
suggested that partial loss of function mutations in two genes (AMT and PEX7) might be causal 
for ASD whereas total loss of function in these genes is associated with more severe 
developmental phenotypes. 
Due to a limited ancestral gene pool, isolated and endogamous populations have 
frequent runs of homozygosity even when parents are not nominally related. Mapping and WES 
were used in multiplex Amish and Mennonite families to identify candidate genomic regions, and 
variants in those regions were filtered for novel variants (absent from dbSNP) and 
heterozygotes in all healthy population-matched controls.64 The fraction of the genome covered 
by runs of homozygosity is highly variable since even in families not known to be 
consanguineous, some common ancestry may exist. One study selected the 16 patients with 
the highest degree of homozygosity from 1000 Autism Genetic Resource Exchange families and 
performed WES.65 After functional filtering, candidate mutations were validated by targeted 
sequencing in parents and in unaffected siblings to verify segregation with ASD. This approach 
identified candidate missense mutations in four genes that, in a separate cohort, also proved to 
have a higher mutation burden in cases than controls. Together, these studies support a role for 
mutations in identical-by-descent alleles both in consanguineous families and, to some extent, 
in the general population. 
 
Dominant de novo coding variations 
 
Sporadic cases of autism with unrelated parents are likely to be enriched for de novo mutations. 
Although de novo mutations may not be inherited or may arise from germ-line mosaics, they do 
contribute to estimates of ASD heritability because they are usually shared between 
monozygous twins. Several studies have performed whole exome sequencing of trios, 
sometimes including unaffected siblings, in order to identify de novo coding mutations present in 
heterozygous states in affected children,19–23 with some genes later targeted for resequencing.18 
One study performed whole-genome sequencing of concordant monozygous twins and their 
parents.24 Advanced parental age has been associated with a higher total number of de novo 
coding variations in children, both affected and unaffected.19,21–23 Maternal and paternal age 
were found to be strongly correlated with one another,22,23 but the limited number of de novo 
variations that were successfully phased proved to reside overwhelmingly on the paternal 
chromosome,19,22 implicating paternal age as a major contributor to the higher rate of point 
mutations. All studies that compared the rate of de novo mutations in affected versus unaffected 
siblings failed to find evidence of a significantly elevated total number of de novo mutations in 
cases. Rather, those de novo mutations that were detected in the affected sibs showed an 
enrichment for variants of functional importance: nonsense mutations occurred at a much higher 
rate in cases than controls,19,21–23 with variable evidence among studies for a significant 
enrichment of missense mutations.23 Similarly, the de novo mutations in cases showed a 
relative enrichment for occurrence in genes whose products showed protein-protein interactions 
with one another,22 were regulated by FMRP,21 or were involved in chromatin regulation.19,43  
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Dominant, incompletely penetrant inherited mutations 
 
In contrast to the family-based studies discussed above, one study sought to identify ASD 
genes through a case-control design coupled with filtering for genes annotated to belong to 
neurodevelopment pathways.66 This study identified one candidate gene with mutations present 
in multiple cases, but validation sequencing revealed that the mutation was inherited from 
unaffected parents in some cases, implying either false-positive association or a dominant allele 
with incomplete penetrance. 
 
STRUCTURAL VARIATIONS 
 
Studies of variation in genome structure have advanced our understanding of the genetic 
architecture of ASD perhaps more than any other approach. Structural variations (SVs) are 
broadly divided into two categories: unbalanced SVs, which result in regional genomic dosage 
change (that is, in CNVs), and balanced chromosomal rearrangements (BCRs), which involve 
changes in the chromosome structure without significant gain or loss of genetic material. 
Because array comparative genomic hybridization techniques and SNP microarrays have 
allowed for numerous studies of readily detectable CNVs, almost all SV studies to date have 
focused on this class of variants. The elucidation of genes disrupted by BCRs has traditionally 
been more problematic, as these were detectable only by cytogenetic techniques such as 
karyotyping, and characterization of the precise breakpoints required laborious serial positional-
cloning techniques. Innovations in massively parallel sequencing, however, have now enabled 
rapid delineation of these rearrangement events to base-pair resolution.67,68 All initial studies of 
SVs were based on karyotyping, which is limited to microscopically visible changes in the 
chromosomes, typically on the order of 3–10 Mb, depending on banding resolution.69 Previous 
studies by Scherer and colleagues70 established that roughly 7% of ASD cases harbored 
cytogenetically visible chromosome abnormalities, and subsequent efforts reported a consistent 
result (5.8%) in independent ASD cases.32 Several early studies used array-based technologies 
to establish CNVs as a major source of genomic variation,71–73 and such structural changes in 
the chromosomes have been robustly established as highly penetrant contributors to the 
etiology of ASD, as reviewed below.  
 
Copy number variations 
 
Reports of the impact of large, de novo CNVs in ASD have been remarkably consistent74 and 
have been replicated in virtually every study conducted.25,32,75 Genomic imbalances associated 
with ASD generally fit into two classifications: recurrent and nonrecurrent events. Recurrent 
events are predominantly mediated by non-allelic homologous recombination (NAHR), have 
similar rearrangement breakpoints localized to flanking segmental duplications, result in 
reciprocal dosage imbalances (deletion and duplication) in different individuals, and occur at 
measurable frequency in ASD as well as in other disorders and controls. A now classic example 
is the 16p11.2 microdeletion/microduplication syndrome.76 Other regions of recurrent CNVs that 
Talkowski et al 2014 - REVIEW - Autism Spectrum Disorder Genetics   10
have met significant statistical thresholds for association with ASD include 15q11-13,77 
22q11.2,78 and 1q21.1,31 with other recurrent reciprocal dosage regions, such as 17p12, being 
observed in ASD but not yet meeting thresholds of statistical significance. Other loci are 
frequently disrupted by CNVs in ASD (and in related neurodevelopmental disorders that do not 
fit strict diagnostic criteria for ASD) and less commonly in the general population, but since the 
source of this disruption is not NAHR, the CNVs themselves are of different sizes and have 
independent breakpoints. Examples of microdeletion/duplication regions with frequent disruption 
by nonrecurrent CNVs include 9q34.3,79 2q23.1,40 1q21,80 2q33.1,26,81–83 and 16q24.2.29 
The initial CNV studies, and most that followed, revealed association with genomic 
segments that were often large and included many genes and regulatory elements. Much like 
linkage-based approaches, these studies rarely pointed directly to individual genes. More 
recently, the establishment of large patient cohorts has enabled the identification of the 
minimum segments of overlap of nonrecurrent CNVs that define a critical region disrupted 
across many cases. In several recent examples, this strategy has revealed a single gene to be 
a major contributor for a particular microdeletion or microduplication syndrome: MBD5 in 
2q23.1,39,40,84 SATB2 in 2q33.1,82 EHMT1 in 9q34.3,85 CHD1L in 1q21.1,31 and ACACA in 
17p21,31 to name just a few. These discoveries represent a significant advance in ASD genetics 
as well as in the general annotation of the morbid human genome, as they propose the 
hypothesis that many of the recurrent changes to genomic segments associated with human 
disease are attributable to one or a few strong-effect genes in these regions and that those 
genes may eventually serve as targets for rational intervention. While this same approach is not 
applicable to recurrent NAHR-mediated imbalances, given that they are a consequence of 
recurrent breakpoints localized to repeated regions, one study performed a series of individual 
gene knockdowns and overexpression in zebrafish to implicate a single contributory locus, 
KCTD13, in neuroanatomical phenotypes of the recurrent 16p11.2 microdeletion/duplication 
syndrome.86 Similar approaches in other model organisms could provide a feasible approach to 
dissecting NAHR-mediated recurrent rearrangements, although direct association to the ASD 
phenotype is more difficult in such organisms; the studies rely, instead, on a measurable 
morphological trait or biomarker.  
Studies of recurrent CNV have also provided significant insight into the impact of 
dysregulation of gene dosage for a number of ASD-associated loci. In many such regions, risk 
for similar phenotypes is conferred by reciprocal copy-number changes, suggesting the 
presence of genes whose normal function requires tight dosage control. For example, although 
associated with a broad spectrum of psychiatric and developmental phenotypes as well as with 
anthropometric traits,87–89 reciprocal gains and losses of 16p11.2 are both associated with 
increased risk of ASD.76,90 Similar results have been reported for other loci such as 22q11.2, 
15q11-13, 1q21.1, and 2q23.1.25,26,38 The mechanisms by which these reciprocal alterations 
confer similar phenotypes is at present unknown; future transcriptome and network studies of 
ASD, however, may help to elucidate such pathogenic processes. 
 
Balanced chromosomal rearrangements  
 
In contrast to the many CNV studies of ASD, there are precious few studies evaluating the 
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impact of BCRs. This type of structural variation can involve balanced translocations, inversions, 
or excision/insertion events, and in each instance one or more genes can be disrupted at the 
breakpoints in a relatively balanced manner. BCRs have typically been identified clinically at 
microscopic resolution by karyotyping, which has significantly limited the capacity to define 
individual loci disrupted at the breakpoints without labor and cost-intensive positional cloning 
studies. Even so, positional cloning studies have uncovered a number of highly penetrant gene 
defects contributing to ASD, including those in AUTS2,91, NRXN1,92, and EHMT1.85 Recently, 
methodological manipulation of next-generation sequencing data has enabled detection of 
BCRs at sequence-based resolution.26,67,68,93–95 Snyder and colleagues67 initially demonstrated 
the feasibility of the detection of all classes of SV by large-insert, mate-pair sequencing using 
long-read 454 technology. Talkowski and colleagues95 recently performed the first large-scale 
sequencing study of constitutional BCRs, which revealed a highly complex chromosomal 
architecture associated with some BCRs in ASD, including rearrangements as extreme as those 
recently dubbed in cancer as chromothripsis, which have previously been considered as 
catastrophic events that were exclusively somatic in origin.96 Subsequent sequencing of de 
novo BCRs associated with ASD and related neurodevelopmental phenotypes has revealed a 
large number of genes whose disruption potentially contributes to these disorders. In one study 
of 38 subjects, 33 independent genes were found to be disrupted by BCR breakpoints, many of 
which were novel loci not previously associated with ASD, including as CHD8, KIRREL3, 
METTL2B, and many others.26 The primary hurdle in these studies, much like exome-
sequencing studies, is to distinguish, among rare or private loss-of-function mutations, those 
that represent highly penetrant pathogenic variation or moderately penetrant 
oligogenic/polygenic risk factors from those that are benign and well tolerated. This study used 
a convergent genomics approach, nominating loci from BCR sequencing and then interpreting 
the significance of the locus by analyzing gene expression, CNV, and GWAS. For many of the 
33 genes, this approach identified a significantly increased CNV burden among independent 
cases compared to controls. Importantly, the GWAS portion of the study also found, when 
considering those 33 genes, a significant association of ASD with common SNP alleles, 
suggesting that in some individuals the outright inactivation of a gene, and in many more 
persons the polymorphic variation of the same gene, can contribute to the risk of 
neurodevelopmental abnormality. These data firmly support the hypothesis that many ASD-
associated SVs disrupt genes that are under tight dosage regulation, and that subtle or 
profound perturbations of their normal dosage for expression can confer risk regarding a 
spectrum of neurodevelopmental phenotypes, including ASD. 
 
FUNCTIONAL AND CLINICAL IMPLICATIONS 
 
Much of the neurobiological work in ASD has suggested a pathogenic process that disrupts the 
development and function of neuronal synapses, yet one that leads specifically to ASD—whose 
clinical definition is distinct from other neurodevelopmental syndromes and genomic disorders. 
In many ways, genetic discoveries to date have supported this hypothesis, but they have also 
offered a much broader and more complicated perspective on ASD etiology and its resultant 
clinical implications. In some ways they have come to challenge established dogma.  
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Mutations in genes encoding members of protein families involved in cell signaling, cell 
adhesion, and synaptic function or plasticity—including SHANK,25,54,97–101 neurexins,92,102,103 
neuroligin proteins,53,104 glutamate receptors,20,26 BDNF,105 and KIRREL3,26 along with members 
of mTOR and FMRP signaling pathways106—have been strongly aligned with the standard 
hypothesis. All of these proteins play a role in the interconnected network of proteins related to 
synaptic function, and many have been specifically implicated in ASD.107 
 A significant number of genetic discoveries in ASD suggest, however, that diverse 
biological pathways contribute to this disorder and that many ASD genes have a wider 
etiological role in a spectrum of human developmental abnormalities and psychopathology. 
Gene-network analyses and gene-set enrichment analyses—performed on genes associated 
with ASD via mutations or transcriptomics—have implicated a variety of networks and pathways 
as associated with autism.25,42,43,108 Among the most statistically significant risk factors 
discovered to date is CHD8, a chromodomain helicase involved in chromatin remodeling and 
transcriptional repression that was discovered as direct disruption by translocation in an ASD 
subject26 and as a de novo loss-of-function mutation in multiple ASD exome-sequencing 
studies.18,19,22,23 CHD8 was also associated with an increased CNV burden (from both deletion 
and duplication) in ASD subjects and with macrocephaly and various developmental 
outcomes.18,26 Other genes, such as TCF4, also present a complex picture from both 
neurobiological and clinical perspectives. Point mutations in TCF4, which encodes a 
transcriptional regulator, have been shown to result in Pitt-Hopkins syndrome;109,110 structural 
variations have been associated with ASD and other neurodevelopmental phenotypes;26,109 and 
common variants have been among the most significant genome-wide significant risk factors for 
schizophrenia and other psychiatric disorders.44,111 A similar mutational spectrum (translocation, 
deletion, duplication, LoF mutation, non-synonymous mutation) has been shown to disrupt 
MBD5 and result in ASD, intellectual disability, epilepsy, and even later-onset neurobehavioral 
regression.26,39,40,84,112,113 MBD5 encodes a member of the methyl CpG-binding domain family of 
proteins that includes MeCP2, a known causal locus in Rett’s syndrome. Numerous additional 
genes encoding transcriptional regulators and chromatin modifiers have emerged from SV and 
exome-sequencing studies as implicated in ASD and also in diverse other developmental and 
psychiatric phenotypes. 
 How these proteins might comport with a final common pathway model of ASD 
associated with synaptic dysfunction is unclear, given that their role in gene regulation is not 
specific to synapse-related proteins; this area of research is active and ongoing. Similarly, the 
links between ASD and other developmental phenotypes (and also psychiatric traits) are now 
well recognized from numerous CNV, BCR, and GWAS studies, as reviewed above. One open 
area of study is to determine whether there are definable endophenotypes with distinct genetic 
etiologies embedded among these broader disease phenotypes. Another is to define the genetic 
modifiers or environmental effects that may predispose an individual toward specific phenotypic 
outcomes. Given the complex biological pathways implicated in ASD etiology to date, 
integration of the complete genetic background of potentially at-risk individuals, leading to 
defined risks for specific phenotypic outcomes, is a much needed avenue of research in the 
coming years.  
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CONCLUSIONS 
 
As reviewed above, the discovery of novel genetic factors contributing to ASD etiology has 
yielded remarkable insight in the last several years. Much debate remains as to the precise 
genetic architecture of ASD. The models being investigated range from ones in which common 
variation explains the largest proportion of disease risk to ones that implicate rare, but relatively 
penetrant, risk factors that individually explain little of the overall disease risk but that collectively 
are quite important. However, the advancement of genomic technologies and the capacity to 
perform unbiased genome-wide surveys for genomic variants that contribute risk to ASD—
unfettered by prior neurobiological hypotheses—has largely put the question of whether ASD 
has a genetic basis to rest, which in itself is perhaps the most significant breakthrough of the 
last half-decade in ASD genetics.  
In all of the large studies reviewed above, each of the individual genetic alterations 
identified explains a meaningful, but still small, proportion of the overall disease variance, with 
the most common risk factors, such as 16p11.2 alterations, accounting for about 1% of all ASD 
cases. However, it is important to recognize several considerations. All approaches discussed 
(GWAS, exome, and SV) have been applied in underpowered studies that could be expected to 
detect only the strongest, most frequent contributors. The evidence from many disorders, 
however—including, most recently, from psychiatric disorders such as schizophrenia—indicates 
that polygenic effects are relatively weak but are increasingly detectable with adequate 
statistical power. Also, published studies of rare exome variants have investigated the risk 
associated with de novo loss-of-function mutations and have not performed tests adequately 
powered for the full mutational spectrum, including synonymous, non-synonymous, and 
inherited variants, though such studies are ongoing. Similarly, studies of SVs have generally not 
accounted for small or multi-allelic CNVs, or for recurrent BCRs. Finally, submicroscopic 
balanced events and small CNVs are not accessible to current methodologies and have not 
been evaluated in any capacity to date, although such studies are also ongoing. The discoveries 
to date in the genetics of ASD thus show great promise, with equally high anticipation of further 
contributions from future studies, especially those that address the interaction of genetic 
background and environmental factors that drive phenotypic outcomes. The discovery of a 
strong association between ASD and genes involved in epigenetic regulation opens at least one 
route to exploring potential environmental influences on such regulation. Nonetheless, despite 
all of these advances in identifying the genetic predispositions to ASD, the ultimate target of 
rational therapeutics remains a distant goal.  
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